Noninvasive characterization of graft steatosis after liver transplantation

Karlas, Thomas; Kollmeier, J.; Böhm, Stephan; Müller, J.; Kovacs, Peter; Tröltzsch, Matthias; Weimann, A.; Bartels, Michael; Rosendahl, Jonas; Mössner, Joachim; Berg, Thomas; Keim, Volker; Wiegand, Johannes

doi:10.3109/00365521.2014.983156

Cited by 31 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparable results were recently obtained by Karlas et al . in a study performed in transplanted patients, which demonstrated that graft recipients bearing the PNPLA3 p.148M allele are at risk of increased VTCE‐quantified liver steatosis and stiffness.…”

Section: Discussionmentioning

confidence: 95%

The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP)

Arslanow

Stokes

Weber

et al. 2015

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP)

Arslanow

Stokes

Weber

et al. 2015

Liver International

View full text Add to dashboard Cite

show abstract

“…In this direction, the development of diagnostic algorithms with the use non-invasive tools is warranted. Karlas et al [ 70 ] demonstrated that modern non-invasive liver graft assessments such as hepatic ultrasound and transient elastography might be able to properly detect both steatosis and graft fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant

Gitto

Villa

2016

IJMS

View full text Add to dashboard Cite

Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage liver disease, with or without hepatocellular carcinoma. Increase of body weight, onset of insulin resistance and drug-induced alterations of metabolism are reported in liver transplant recipients. In this context, post-transplant diabetes mellitus, hyperlipidemia, and arterial hypertension can be often diagnosed. Multifactorial illnesses occurring in the post-transplant period represent significant causes of morbidity and mortality. This is especially true for metabolic syndrome. Non-alcoholic steatosis and steatohepatitis are hepatic manifestations of metabolic syndrome and after liver transplant both recurrent and de novo steatosis can be found. Usually, post-transplant steatosis shows an indolent outcome with few cases of fibrosis progression. However, in the post-transplant setting, both metabolic syndrome and steatosis might play a key role in the stratification of morbidity and mortality risk, being commonly associated with cardiovascular disease. The single components of metabolic syndrome can be treated with targeted drugs while lifestyle intervention is the only reasonable therapeutic approach for transplant patients with non-alcoholic steatosis or steatohepatitis.

show abstract

“…Karlas et al evaluated post‐LT steatosis by TE using CAP measurements in a population of 204 patients who underwent LT, 50% of whom were transplanted for alcoholic cirrhosis and only 2% transplanted for NASH. At the time of the study, CAP was not available using the XL probe and thus only the M probe was used.…”

Section: Methodsmentioning

confidence: 99%

A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post–liver transplant patient

Winters

Mittal

Schiano

2019

Clinical Transplantation

View full text Add to dashboard Cite

Liver biopsy is considered the gold standard method for diagnosing and staging liver disease, particularly in the post-liver transplant setting. Given the invasive nature of biopsy, alternate means for accurately assessing liver fibrosis and steatosis are preferred especially as the number of patients with fatty liver disease is increasing.Transient elastography has been validated as a useful tool for evaluation of liver fibrosis, as has controlled attenuation parameter index as a tool for assessing steatosis. It is a non-invasive, rapid, and highly reproducible approach to demonstrate the presence of fibrosis among non-transplant patients with chronic liver disease of various etiologies. However, it has not yet found wide acceptance in liver transplant recipients. There are few published studies evaluating the merits and applicability of transient elastography to assess allografts after liver transplantation. We review the published data on the use of transient elastography with concurrent controlled attenuation parameter in liver transplant recipients and recommend its greater use to follow allograft function over time.

show abstract

Noninvasive characterization of graft steatosis after liver transplantation

Abstract: Modern noninvasive liver graft assessment frequently detects hepatic steatosis, which is associated with graft fibrosis, components of the metabolic syndrome and recipient PNPLA3 rs738409 genotype, especially in ALC patients.

Cited by 31 publications

References 38 publications

The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP)

The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP)

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant

A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post–liver transplant patient

Contact Info

Product

Resources

About